Skip to main content

Advertisement

Table 1 Characteristics of patients and controls

From: Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis

Characteristics Early rheumatoid arthritis PLA (n = 37) Early rheumatoid arthritis ADA (n = 39) Chronic rheumatoid arthritis (n = 15) Healthy volunteers (n = 34)
Age, years 54 (37 to 65) 56 (38 to 62) 56 (45 to 64) 54 (38 to 62)
Gender, % female 78 64 80 67
Disease duration at inclusion, months 2.7 (1.4 to 4.3) 2.9 (1.6 to 4.4) 234 (120 to 342) NA
Disease scores     
DAS28 score, baseline 5.6 (4.9 to 5.8) 5.4 (4.8 to 6.4) 3.0 (2.2 to 3.9) NA
DAS28 score, 3 months 2.3 (1.9 to 2.9) 2.0 (1.8 to 2.7) NA NA
DAS28 score, 12 months 2.2 (1.9 to 3.4) 1.9 (1.8 to 2.5) NA NA
Remission, 12 months, % 56 52 NA NA
HAQ score, baseline, range 0 to 3 0.9 (0.6 to 1.3) 1.1 (0.8 to 1.5) 1.0 (0.2 to 2.0) NA
HAQ score, 3 months, range 0 to 3 0.1 (0.0 to 0.6) 0.2 (0.0 to 0.38) NA NA
HAQ score, 12 months, range 0 to 3 0.1 (0 to 0.5) 0.0 (0.0 to 0.4) NA NA
Treatment dose     
MTX, 12 months, mg/week 20.0 (15.5 to 20.0) 20.0 (18.8 to 20.0) NA NA
Cumulative dose of intra-articular betamethasone, 12 months, ml 8.0 (5.0 to 12.5) 5.0 (3.0 to 10.0) NA NA
Laboratory findings at baseline     
IgM-RF-positive, % 84 67 74 NA
ACPA-positive, % 81 56 74 NA
  1. Results are presented as median (SD) or percent. Statistical difference in anti-citrullinated protein antibody (ACPA)-positive in the patient group receiving placebo and methotrexate (PLA) and the patient group receiving adalimumab and methotrexate (ADA) at baseline (P <0.05). MTX, methotrexate; ADA, adalimumab; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; DAS28CRP, CRP-based DAS28; Remission, American College of Rheumatology/European League Against Rheumatism remission (Boolean, 28 joints); HAQ, health assessment questionnaire; IgM-RF, IgM rheumatoid factor; NA, not applicable or not available.